Galmed Pharmaceuticals Ltd.

NasdaqCM:GLMD Rapporto sulle azioni

Cap. di mercato: US$1.8m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Galmed Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Allen Baharaff

Amministratore delegato

US$1.4m

Compenso totale

Percentuale dello stipendio del CEO40.6%
Mandato del CEO24.7yrs
Proprietà del CEOn/a
Durata media del management7.5yrs
Durata media del Consiglio di amministrazione8.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

May 16
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 06
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Galmed GAAP EPS of -$0.15 beats by $0.09

Aug 04

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

May 03
Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 15
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Oct 02
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

May 20
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

Galmed gets greenlight for late-stage Aramchol NASH trial in China

May 03

What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

Feb 04
What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Dec 06
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Galmed EPS misses by $0.02

Nov 12

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Allen Baharaff rispetto agli utili di Galmed Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$1mUS$551k

-US$7m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$605k

-US$18m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$3mUS$632k

-US$32m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$503k

-US$29m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$1mUS$486k

-US$20m

Sep 30 2019n/an/a

-US$16m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$2mUS$384k

-US$10m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$12m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017US$1mUS$384k

-US$12m

Compensazione vs Mercato: La retribuzione totale di Allen ($USD 1.36M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Allen è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Allen Baharaff (59 yo)

24.7yrs

Mandato

US$1,356,184

Compensazione

Mr. Allen Baharaff has been the Chief Executive Officer of Galmed Pharmaceuticals Ltd. since January 2012 and has been its President since March 2015. Mr. Baharaff co-founded the Galmed Pharmaceuticals Ltd...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Allen Baharaff
Co-Founder24.7yrsUS$1.36mNessun dato
Doron Cohen
Chief Financial Officer2.6yrsUS$273.81k0.0032%
$ 57.5
Guy Nehemya
COO & Data Protection Officer7.5yrsUS$374.78k0.0059%
$ 104.8
Yohai Stenzler
Chief Accounting Officer2.6yrsUS$378.32k0.0059%
$ 104.8
Liat Hayardeny
Chief Scientific Officer8yrsUS$114.69k0%
$ 0
Tali Gorfine
Medical Consultant7.5yrsUS$382.51kNessun dato

7.5yrs

Durata media

55.5yo

Età media

Gestione esperta: Il team dirigenziale di GLMD è esperto e expertise (durata media dell'incarico 7.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Allen Baharaff
Co-Founderno dataUS$1.36mNessun dato
David Sidransky
Lead Independent Director10.3yrsNessun dato0.0079%
$ 142.0
Carol Brosgart
Independent Director7.3yrsNessun dato0%
$ 0
José Mato de la Paz
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Scott L. Friedman
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Arun Sanyal
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Vlad Raziu
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Shmuel Nir
Independent Director17.7yrsNessun dato0.0079%
$ 142.0
Amir Poshinski
Independent Director4.3yrsNessun dato0%
$ 0
Shomron Ben-Horin
Member of Scientific Advisory Boardno dataNessun datoNessun dato

8.8yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GLMD sono considerati esperti (durata media dell'incarico 8.7 anni).